Can Hims & Hers Stock Recover Through a Strategic Pivot?
Published on 09/14/2025 at 20:18 | Redaktion boerse-global.deThe telehealth company Hims & Hers is embarking on a significant strategic shift, moving its focus toward men’s hormone therapies. This new direction follows a challenging period for its once-lucrative weight-loss medication business, which had previously unsettled investors.
In a strategic move announced earlier this week, Hims & Hers revealed an exclusive partnership with Marius Pharmaceuticals. The core of this alliance is the planned exclusive distribution of KYZATREX®, an FDA-approved oral testosterone medication, through the Hims & Hers digital platform starting in 2026.
This initiative targets a substantial market opportunity. An estimated 20 million men in the United States are affected by low testosterone levels. The company already provides access to individually dosed Enclomiphene formulations on its platform, a... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
